Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
VivoSim Labs ( (VIVS) ) has issued an announcement.
On August 7, 2025, VivoSim Labs appointed Tony Lialin as Chief Commercial Officer, effective August 11, 2025. Lialin, with over two decades of experience in commercializing life science platforms, will lead the company’s go-to-market strategy and the expansion of its San Diego-based services. VivoSim Labs is positioned to capitalize on the growing market for 3D human tissue models, particularly in liver and intestine toxicology services, driven by regulatory changes and increased adoption of non-animal methodologies. The company applies AI to enhance its models, providing decision-ready insights to pharmaceutical partners.
More about VivoSim Labs
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates using three-dimensional human tissue models of liver and intestine. The company offers liver and intestinal toxicology insights through its new approach methodologies models and operates from San Diego, CA.
Average Trading Volume: 65,317
Technical Sentiment Signal: Sell
Current Market Cap: $4.56M
See more data about VIVS stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money